Skip to content

Analyses of Cerebrospinalfluid in Patients With Delirium

MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05060614
Enrollment
700
Registered
2021-09-29
Start date
2016-09-01
Completion date
2027-12-30
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Brief summary

The current project aims to measure biomarkers in the cerebrospinalfluid (CSF) and serum samples from patients with delirium. We hope to uncover new insights into the pathophysiology of delirium and explore its link to dementia.

Detailed description

Delirium is a common and serious complication to acute illness, and is characterized by acute disturbances in attention, awareness, and cognition. Dementia is a major risk factor of delirium, and delirium increases the risk of dementia progression and development. As the conditions share both clinical and epidemiological features, some researchers suggest that also pathophysiological links are shared. Understanding delirium pathophysiology, which is poorly understood, may thus help elucidate early molecular mechanisms in dementia. This study aims to to increase our understanding of the pathophysiology of delirium and molecular links between delirium and dementia, by exploring cerebrospinal fluid (CSF) biomarkers.

Interventions

PROCEDUREHip fracture surgery

Hip fracture surgery

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients with acute hip fracture

Exclusion criteria

* Moribund patients. * Lack of consent

Design outcomes

Primary

MeasureTime frameDescription
DeliriumDaily during hospital stay (pre-/and postoperatively) until 5 days after surgery (or discharge)Pre- and postoperative delirium

Secondary

MeasureTime frameDescription
DementiaCognitive changes the first 48 months after inclusionIncident dementia

Countries

Norway

Contacts

Primary ContactLeiv O Watne, PhD
l.o.watne@gmail.com40203712

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026